Role of Crk oncogene product in physiologic signaling

Critical Reviews in Oncogenesis

Volumn 8, Issue 4, 1997, Pages 329-342

  Kiyokawa, Etsuko ^a   Mochizuki, Naoki ^b   Kurata, Takeshi ^a   Matsuda, Michiyuki ^a,b  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

c Crk; CrkI; CrkII; CrkL; Oncogene; SH2; SH3; v Crk

Indexed keywords

ADAPTOR PROTEIN; B LYMPHOCYTE ANTIGEN; CYTOKINE; GROWTH FACTOR RECEPTOR; INSULIN RECEPTOR; INTEGRIN; NERVE GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; T LYMPHOCYTE RECEPTOR;

ARTICLE; CARCINOGENESIS; GENE STRUCTURE; LIGAND BINDING; ONCOGENE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RECEPTOR BINDING; SECOND MESSENGER; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

EID: 0031392796     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v8.i4.30     Document Type: Article

References (95)

1. Anafi, M., M. K. Rosen, G. D. Gish, L. E. Kay, and T. Pawson: A potential SH3 domain- binding site in the Crk SH2 domain. J. Biol. Chem., 271:21365-21374 (1996).
2. Anderson, D., C. A. Koch, L. Grey, C. Ellis, M. F. Moran, and T. Pawson: Binding of SH2 domains of phospholipase Cγl, GAP, and src to activated growth factor receptors. Science, 250:979-982 (1990).
3. Andoniou, C. E., C. B. F. Thien, and W. Y. Langdon: The two major sites of cbl tyrosine phosphorylation in abl-transformed cells select the crkL SH2 domain. Oncogene, 12(9):1981-1989 (1996).
4. Barber, D. L., J. M. Mason, T. Fukazawa, K. A. Reedquist, B. J. Druker, H. Band, and A. D. D'Andrea: Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins. Blood, 89:3166-3174 (1997).
5. Beitner-Johnson, D., V. A. Blakesley, Z. ShenOrr, M. Jimenez, B. Stannard, L. M. Wang, J. Pierce, and D. Le Roith: The protooncogene product c-Crk associates with insulin receptor substrate-1 and 4PS modulation by insulin growth factor-1 (IGF) and enhanced IGF-1 signaling. J. Biol. Chem., 271:9287-9290 (1996).
6. Birge, R. B., J. E. Fajardo, B. J. Mayer, and H. Hanafusa: Tyrosine-phosphorylated epidermal growth factor receptor and cellular p130 provide high affinity binding substrates to analyze crk-phosphotyrosine-dependent interactions in vitro. J. Biol. Chem., 267:10588-10595 (1992).
7. Birge, R. B., J. E. Fajardo, C. Reichman, S. E. Shoelson, Z. Songyang, L. C. Cantley, and H. Hanafusa: Identification and characterization of a high-affinity interaction between v-Crk and tyrosine-phosphorylated paxillin in CT10-transformed fibroblasts. Mol. Cell. Biol., 13:4648-4656 (1993).
8. Blakesley, V. A., D. Beitnerjohnson, J. R. VanBrocklyn, S. Rani, Z. ShenOrr, B. S. Stannard, S. Spiegel, and D. Le Roith: Sphingosine 1-phosphate stimulates tyrosine phosphorylation of Crk. J. Biol. Chem., 272:16211-16215 (1997).
9. Boussiotis, V. A., G. J. Freeman, A. Berezovskaya, D. L. Barber, and L. M. Nadler: Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science, 278:124-128 (1997).
10. Buday, L., A. Khwaja, S. Sipeki, A. Farago, and J. Downward: Interactions of Cbl with two adaptor proteins, Grb2 and Crk, upon T cell activation. J. Biol. Chem., 271:6159-6163 (1996).
11. Burridge, K., C. E. Turner, and L. H. Romer: Tyrosine phosphorylation of paxillin and pp125(FAK) accompanies cell adhesion to extracellular matrix - a role in cytoskeletal assembly. J. Cell Biol., 119:893-903(1992).
12. Cas by bombesin, lysophosphatidic acid, phorbol esters, and platelet-derived growth factor. Signaling pathways and formation of a p130(cas)-Crk complex. J. Biol. Chem., 272:9363-9370 (1997).
13. Cicchetti, P., B. J. Mayer, G. Thiel, and D. Baltimore: Identification of protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho. Nature (London), 257:803-806 (1992).
14. Clark, E. A. and J. S. Brugge: Integrins and signal transduction pathways: the road taken. Science, 268:233-239 (1995).
15. Claude, A.: Preparation of an active agent from inactive tumor extracts. Science, 85:294-295 (1937).
16. Cook, S. J., B. Rubinfeld, I. Albert, and F. McCormick: RapV12 antagonizes Ras-dependent activation of ERK1 and ERK2 by LPA and EGF in Rat-1 fibroblasts. EMBO J., 12:3475-3485 (1993).
17. Dejong, R., L. Haataja, J. W. Voncken, N. Heisterkamp, and J. Groffen: Tyrosine phosphorylation of murine crkl. Oncogene, 11:1469-1474 (1995).
18. Erickson, M. S., B. J. Galletta, and S. M. Abmayr: Drosophila myoblast city encodes a conserved protein that is essential for myoblast fusion, dorsal closure, and cytoskeletal organization. J. Cell Biol., 138:589-603 (1997).
19. Evans, E. K., W. Lu, S. L. Strum, B. J. Mayer, and S. Kornbluth: Crk is required for apoptosis in Xenopus egg extracts. EMBO J., 16:230-241 (1997).
20. Fazioli, F., L. Minichiello, B. Matoskova, W. T. Wong, and P. P. Di Fiore: eps15, a novel tyrosine kinase substrate, exhibits transforming activity. Mol. Cell. Biol., 13:5814-5828 (1993).
21. Feig, L. A. and B. Schaffhausen: Signal transduction - the hunt for ras targets. Nature (London), 370:508-509 (1994).
22. Feller, S. M., B. Knudsen, and H. Hanafusa: c-Abl kinase regulates the protein binding activity of c-Crk. EMBO J., 13:2341-2351 (1994a).
23. Feller, S. M., R. B. Ren, H. Hanafusa, and D. Baltimore: SH2 and SH3 domains as molecular adhesives: the interactions of crk and abl. Trends Biochem. Sci., 19:453-458 (1994b).
24. Feller, S. M., B. Knudsen, and H. Hanafusa: Cellular proteins binding to the first src homology 3 (SH3) domain of the protooncogene product c-crk indicate crk-specific signaling pathways. Oncogene, 10:1465-1473 (1995).
25. Gotoh, T., S. Hattori, S. Nakamura, H. Kitayama, M. Noda, Y. Takai, K. Kaibuchi, H. Matsui, O. Hatase, H. Takahashi, T. Kurata, and M. Matsuda: Identification of Rap1 as a target for Crk SH3 domain-binding guanine nucleotide-releasingfactor, C3G. Mol. Cell. Biol., 15:6746-6753 (1995).
26. Gotoh, T., Y. Niino, M. Tokuda, O. Hatase, S. Nakamura, M. Matsuda, and S. Hattori: Activation of R-Ras by ras-guanine nucleotide-releasing factor. J. Biol. Chem., 272:18602-18607 (1997).
27. Greulich, H. and H. Hanafusa: A role for Ras in v-Crk transformation. Cell Growth Differ., 7:1443-1451 (1996).
28. Cas, a substrate associated with v-Src and v-Crk, localizes to focal adhesions and binds to focal adhesion kinase. J. Biol. Chem., 271(23):13649-13655 (1996).
29. Hasegawa, H., E. Kiyokawa, S. Tanaka, K. Nagashima, N. Gotoh, M. Shibuya, T. Kurata, and M. Matsuda: DOCK180, a major CRK-binding protein, alters cell morphology upon translocation to the membrane. Mol. Cell. Biol., 16:1770-1776 (1996).
30. Hunter, A. J. and Y. Shimizu: Alpha 4 beta 1 integrin-mediated tyrosine phosphorylation in human T cells: characterization of Crk- and Fyn-associated substrates (pp105, pp115, and human enhancer of filamentation-1) and integrin-dependent activation of p59fyn1. J. Immunol., 159:4806-4814 (1997).
31. Ichiba, T., Y. Kuraishi, O. Sakai, S. Nagata, J. Groffen, T. Kurata, S. Hattori, and M. Matsuda: Enhancement of guanine-nucleotide exchange activity of C3G for Rap1 by the expression of Crk, CrkL, and Grb2. J. Biol. Chem., 272:22215-22220 (1997).
32. Ishiki, M., T. Sasaoka, H. Ishihara, T. Imamura, I. Usui, Y. Takata, and M. Kobayashi: Evidence for functional roles of Crk-II in insulin and epidermal growth factor signaling in Rat-1 fibroblasts overexpressing insulin receptors. Endocrinology, 138:4950-4958 (1997).
33. Joneja, B. and D. M. Wojchowski: Mitogenic signaling and inhibition of apoptosis via the erythropoietin receptor Box-1 domain. J. Biol. Chem., 272:11176-11184 (1997).
34. Cas-related docking protein family, and its subsequent binding to the Src homology 2 domain of c-Crk. Eur. J. Immunol., 27:2113-2117 (1997).
35. Kawata, M., Y. Matsui, J. Kondo, T. Hishida, Y. Teranishi, and Y. Takai: A novel small molecular weight GTP-binding protein with the same putative effector domain as the ras proteins in bovine brain membranes. Purification, determination of primary structure, and characterization. J. Biol. Chem., 263:18965-18971 (1988).
36. Cas with Crk and Grb2 adaptor proteins. Oncogene, 12:2491-2498 (1996).
37. Kitayama, H., Y. Sugimoto, T. Matsuzaki, Y. Ikawa, and M. Noda: A ras-related gene with transformation suppressor activity. Cell, 56:77-84 (1989).
38. Kizaka-Kondoh, S., M. Matsuda, and H. Okayama: CrkII signals from epidermal growth factor receptor to Ras. Proc. Natl. Acad. Sci. U.S.A., 93:12177-12182 (1996).
39. Knudsen, B. S., S. M. Feller, and H. Hanafusa: Four proline-rich sequences of the guanine-nucleotide exchange factor C3G bind with unique specificity to the first src homology 3 domain of crk. J. Biol. Chem., 269:32781-32787 (1994).
40. Knudsen, B. S., J. Zheng, S. M. Feller, J. P. Mayer, S. K. Burrell, D. Dowburn, and H. Hanafusa: Affinity and specificity requirements for the first Src homology 3 domain of the Crk proteins. EMBO J., 14:2191-2198 (1995).
41. Margolis, B., O. Silvennoinen, F. Comoglio, C. Roonprapunt , E. Skolnik, A. Ullrich, and J. Schlessinger: High-efficiency expression/cloning of epidermal growth factor- receptor-binding proteins with Src homology 2 domains. Proc. Natl. Acad. Sci. U.S.A., 89:8894-8898 (1992).
42. Matsuda, M., Y. Hashimoto, K. Muroya, H. Hasegawa, T. Kurata, S. Tanaka, S. Nakamura, and S. Hattori: CRK binds to two guanine nucleotide-releasing proteins for the Ras family and modulates nerve growth factor-induced activation of Ras in PC12 cells. Mol. Cell. Biol., 14:5495-5500 (1994).
43. gag-crk, to a broad range of phosphotyrosine-containing proteins. Science, 248:1537-1539(1990).
44. Matsuda, M., B. J. Mayer, and H. Hanafusa: Identification of domains of the v-crk oncogene product sufficient for association with phosphotyrosine-containing proteins. Mol. Cell. Biol., 11:1607-1613 (1991).
45. Matsuda, M., S. Ota, R. Tanimura, H. Nakamura, K. Matuoka, T. Takenawa, K. Nagashima, and T. Kurata: Interaction between the amino terminal SH3 domain of CRK and its natural target proteins. J. Biol. Chem., 271:14468-14472 (1996).
46. Matsuda, M., S. Tanaka, S. Nagata, A. Kojima, T. Kurata, and M. Shibuya: Two species of human CRK cDNA encode proteins with distinct biological activities. Mol. Cell. Biol., 12:3482-3489 (1992).
47. Mayer, B. J., M. Hamaguchi, and H. Hanafusa: A novel viral oncogene with structural similarity to phospholipase C. Nature (London), 332:272-275 (1988).
48. gag-crk, a novel oncogene product with sequence similarity to a putative modulatory domain of protein-tyrosine kinases and phospholipase C. Cold Spring Harbor Symp. Quant. Biol., 53:907-914 (1989).
49. Mayer, B. J. and H. Hanafusa: Association of the v-crk oncogene product with phosphotyrosine-containing proteins and protein kinase activity. Proc. Natl. Acad. Sci. U.S.A., 87:2638-2642 (1990a).
50. Mayer, B. J. and H. Hanafusa: Mutagenic analysis of the v-crk oncogene: requirement for SH2 and SH3 domains and correlation between increased cellular phosphotyrosine and transformation. J. Virol., 64:3581-3589 (1990b).
51. Nagase, T., N. Seki, K. Ishikawa, M. Ohira, Y. Kawarabayasi, O. Ohara, A. Tanaka, H. Kotani, N. Miyajima, and N. Nomura: Prediction of the coding sequences of unidentified human genes. VI. The coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of cDNA clones from cell line KG-1 and brain. DNA Res., 3:321-354 (1996).
52. Nichols, G. L., M. A. Raines, J. C. Vera, L. Lacomis, P. Tempst, and D. W. Golde: Identification of CRKL as the constitutively phosphorylated 39-kd tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood, 84:2912-2918 (1994).
53. Cas, a src homology 3-containing molecule having multiple src homology 2-binding motifs. J. Biol. Chem., 270:15398-15402 (1995).
54. Oda, T., C. Heaney, J. R. Hagopian, K. Okuda, J. D. Griffin, and B. J. Druker: Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J. Biol. Chem., 269:22925-22928 (1994).
55. Ogawa, S., H. Toyoshima, H. Kozutsumi, K. Hagiwara, R. Sakai, T. Tanaka, N. Hirano, H. Mano, Y. Yazaki, and H. Hirai: The c-terminal SH3 domain of the mouse ccrk protein negatively regulates tyrosine-phosphorylation of crk associated p130 in rat 3Y1 cells. Oncogene, 9:1669-1678 (1994).
56. Cas. Involvement of phosphatidylinositol 3′-kinase and actin cytoskeleton. J. Biol. Chem., 272:25993-25998 (1997).
57. Ota, S., S. Kizaka-Kondoh, Y. Hashimoto, H. Nishihara, K. Nagashima, T. Kurata, H. Okayama, and M. Matsuda. Constitutive association of EGF receptor with the CrkII-23 mutant that inhibits transformation of NRK cells by EGF and TGF-β. Cell. Signal., (in press), 1998.
58. Parrizas, M., V. A. Blakesley, D. Beitnerjohnson, and D. Le Roith: The protooncogene Crk-II enhances apoptosis by a ras-dependent, Raf-1/MAP kinase-independent pathway. Biochem. Biophys. Res. Commun., 234:616-620 (1997).
59. Pawson, T. and J. Schlessinger: SH2 and SH3 domains. Curr. Biol., 3:434-442 (1993).
60. Pizon, V., P. Chardin, I. Lerosey, B. Olofsson, and A. Tavitian: Human cDNAs rap1 and rap2 homologous to the Drosophila gene Dras3 encode proteins closely related to ras in the effector region. Oncogene, 3:201-204 (1988).
61. Rani, C. S. S., F. Wang, E. Fuior, A. Berger, J. Wu, T. W. Sturgill, D. Beitnerjohnson, D. Le Roith, L. Varticovski, and S. Spiegel: Divergence in signal transduction pathways of platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) receptors - involvement of sphingosine 1-phosphate in PDGF but not EGF signaling. J. Biol. Chem., 272:10777-10783 (1997).
62. Reedquist, K. A., T. Fukazawa, G. Panchamoorthy, W. Y. Langdon, S. E. Shoelson, B. J. Druker, and H. Band: Stimulation through the T cell receptor induces Cbl association with Crk proteins and the guanine nucleotide exchange protein C3G. J. Biol. Chem., 271:8435-8442 (1996).
63. Reichman, C. T., B. J. Mayer, S. Keshau, and H. Hanafusa: The product of the cellular crk gene consists primarily of SH2 and SH3 regions. Cell Growth Differ., 3:451-460 (1992).
64. Ren, R., B. J. Mayer, P. Cicchetti, and D. Baltimore: Identification of a 10 amino acid proline-rich SH3 binding site. Science, 259:1157-1161 (1993).
65. Ren, R., Z. Ye, and D. Baltimore: Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites. Gene.Dev., 8:783-795 (1994).
66. Cas in PC-12 cells. J. Biol. Chem., 271:7375-7380 (1996).
67. Richardson, A. and J. T. Parsons: Signal transduction through integrins: a central role for focal adhesion kinase? Bioessays, 17:229-236 (1995).
68. Rosen, M. K., T. Yamazaki, G. D. Gish, C. M. Kay, T. Pawson, and L. E. Kay: Direct demonstration of an intramolecular SH2-phosphotyrosine interaction in the crk protein. Nature (London), 374:477-479 (1995).
69. Sabe, H., S. E. Shoelson, and H. Hanafusa: Possible v-Crk-induced transformation through activation of Src kinases. J. Biol. Chem., 270:31219-31224 (1995).
70. gag-fps. Mol. Cell. Biol., 6:4396-4408 (1986).
71. Sakai, R., A. Iwamatsu, N. Hirano, S. Ogawa, T. Tanaka, H. Mano, Y. Yazaki, and H. Hirai: A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J., 13:3748-3756 (1994a).
72. Sakai, R., A. Iwamatsu, N. Hirano, S. Ogawa, T. Tanaka, J. Nishida, Y. Yazaki, and H. Hirai: Characterization, partial purification, and peptide sequencing of p130, the main phosphoprotein associated with v-crk oncoprotein. J. Biol. Chem., 269:32740-32746 (1994b).
73. Salgia, R., N. Uemura, K. Okuda, J. L. Li, E. Pisick, M. Sattler, R. Dejong, B. Druker, N. Heisterkamp, L. B. Chen, J. Groffen, and J. D. Griffin: CRKL links p210(BCR/ABL) with paxillin in chronic myelogenous leukemia cells. J. Biol. Chem., 270:29145-29150 (1995).
74. Cas forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J. Biol. Chem., 271:25198-25203 (1996).
75. cbl and the adaptor proteins CRKL and c-CRK link c-ABL, p190(BCR/ABL) and p210(BCR/ABL) to the phosphatidylinositol-3′ kinase pathway. Oncogene, 12X:839X-846X (1996).
76. Sawasdikosol, S., J. H. Chang, J. C. Pratt, G. Wolf, S. E. Shoelson, and S. J. Burakoff: Tyrosine-phosphorylated Cbl binds to Crk after T cell activation. J. Immunol., 157:110-116 (1996).
77. Schaller, M. D. and J. T. Parsons: pp125FAK-dependent tyrosine phosphorylation of paxillin creates a high-affinity binding site for Crk. Mol. Cell. Biol., 15:2635-2645 (1995).
78. Schumacher, C., B. S. Knudsen, T. Ohuchi, P. P. Difiore, R. H. Classman, and H. Hanafusa: The SH3 domain of crk binds specifically to a conserved proline-rich motif in eps15 and eps15R. J. Biol. Chem., 270:15341-15347 (1995).
79. Smit, L., G. vanderHorst, and J. Borst: Formation of Shc/Grb2- and Crk adaptor complexes containing tyrosine phosphorylated Cbl upon stimulation of the B-cell antigen receptor. Oncogene, 13:381-389 (1996a).
80. Smit, L., G. vanderHorst, and J. Borst: Sos, Vav, and C3G participate in B cell receptor-induced signaling pathways and differentially associate with Shc-Grb2, Crk, and Crk-Ladaptors. J. Biol. Chem., 271:8564-8569 (1996b).
81. Songyang, Z., S. E. Shoelson, M. Chaudhuri, G. Gish, T. Pawson, W. G. Haser, F. King, T. Roberts, S. Ratnofsky, R. J. Lechleider, B. G. Neel, R. B. Birge, J. E. Fajardo, M. M. Chou, H. Hanafusa, B. Schaffhausen, and L. C. Cantley: SH2 domains recognize specific phosphopeptide sequences. Cell, 72:767-778 (1993).
82. Stahl, M. L., C. R. Ferenz, K. L. Kelleher, R. W. Kriz, and J. L. Knopf: Sequence similarity of phospholipase C with the noncatalytic region of src. Nature (London), 332:269-272 (1988).
83. Tanaka, S., S. Hattori, T. Kurata, K. Nagashima, Y. Fukui, S. Nakamura, and M. Matsuda: Requirement of both the SH2 and SH3 domains for neuronal differentiation of PC12 cells induced by human CRK protein. Mol. Cell. Biol., 13:4409-4415 (1993).
84. Tanaka, S., T. Morishita, Y. Hashimoto, S. Hattori, S. Nakamura, T. Takenawa, K. Matuoka, M. Shibuya, T. Kurata, K. Nagashima, and M. Matsuda: C3G, a guanine nucleotide releasing protein, binds to the SH3 domains of CRK and ASH/GRB2. Proc. Natl. Acad. Sci. U.S.A., 91:3443-3447 (1994).
85. Tanaka, S., T. Ouchi, and H. Hanafusa: Downstream of Crk adaptor signaling pathway: Activation of Jun kinase by v-Crk through the guanine nucleotide exchange protein C3G. Proc. Natl. Acad. Sci. U.S.A., 94:2356-2361 (1997).
86. Tanaka, S., and H. Hanafusa: Guanine-nucleotide exchange proteib C3G activates JNK1 by a Ras-independent mechanism. JNK1 activation inhibited by kinase negative forms of mlk3 and dlk mixed lineage kinases. J. Biol. Chem., 273:1281-1284 (1998).
87. ten Hoeve, J., C. Morris, N. Heisterkamp, and J. Groffen: Isolation and chromosomal localization of CRKL, a human crk-like gene. Oncogene, 8:2469-2474 (1993).
88. ten Hoeve, J., R. B. Arlinghaus, J. Q. Guo, N. Heisterkamp, and J. Groffen: Tyrosine phosphorylation of CRKL in Philadelphia (+) leukemia. Blood, 84:1731-1736 (1994).
89. Cas. Oncogene, 12:77-86 (1996).
90. van den Berghe, N., R. H. Cool, G. Horn, and A. Wittinghofer: Biochemical characterization of C3G: an exchange factor that discriminates between Rap1 and Rap2 and is not inhibited by Rap1A(S17N). Oncogene, 15:845-850 (1997).
91. Cas signaling complex formation upon integrin-mediated cell adhesion: A role for Src family kinases. Mol. Cell. Biol., 16(6):2606-2613 (1996).
92. Cas and cortactin accompanies integrin-mediated cell adhesion to extracellular matrix. J. Biol. Chem., 270:22259-22262 (1995).
93. Wang, B. L., T. Mysliwiec, S. M. Feller, B. Knudsen, H. Hanafusa, and G. D. Kruh: Proline-rich sequences mediate the interaction of the Arg protein tyrosine kinase with Crk. Oncogene, 13:1379-1385 (1996).
94. Wu, X. D., B. Knudsen, S. M. Feller, J. Zheng, A. Sali, D. Cowburn, H. Hanafusa, and J. Kuriyan: Structural basis for the specific interaction of lysine-containing proline-rich peptides with the n-terminal SH3 domain of c-crk. Structure, 3:215-226 (1995a).
95. Wu, X. D., B. S. Knudson, S. M. Feller, H. Hanafusa, and J. Kuriyan: High resolution crystal structure of a crk SH3 domain with its specific ligand. Protein Eng., 8:38-38 (1995b).